Cargando…
End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s
BACKGROUND: End-stage renal disease is an irreversible status of kidney dysfunction that reduces both renal and non-renal drug clearance. Accumulation of uremic toxins seems to modify the activities of drug-metabolizing cytochrome P450 (CYP) enzymes. The aim of the present work was to refine gene ex...
Autores principales: | Déri, Máté Tamás, Kiss, Ádám Ferenc, Tóth, Katalin, Paulik, József, Sárváry, Enikő, Kóbori, László, Monostory, Katalin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704481/ https://www.ncbi.nlm.nih.gov/pubmed/32638224 http://dx.doi.org/10.1007/s43440-020-00127-w |
Ejemplares similares
-
Relevance of CYP2C9 Function in Valproate Therapy
por: Monostory, Katalin, et al.
Publicado: (2019) -
Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients
por: Incze, Evelyn, et al.
Publicado: (2023) -
Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia
por: Menus, Ádám, et al.
Publicado: (2020) -
Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects
por: Fekete, Ferenc, et al.
Publicado: (2021) -
Optimization of Clonazepam Therapy Adjusted to Patient’s CYP3A Status and NAT2 Genotype
por: Tóth, Katalin, et al.
Publicado: (2016)